Biology subjects

Burkhart, A.

Publications and source records attributed to Burkhart, A..

3 recordsLinked to original sources

bioRxiv2026

Ganglioside profiling by ion mobility and mass spectrometry imaging identifies distinct biomolecular isomers in Niemann-Pick Disease

Gangliosides are glycosphingolipids implicated in the neurodegenerative pathology of Niemann-Pick disease type C2 (NPC2 disease), where accumulation of GM2 and GM3 is a hallmark of disrupted lipid trafficking and disease progression. Some gangliosides are structural isomers with identical molecular composition and mass, making them difficult to distinguish by mass spectrometry imaging (MSI) alone and leaving their spatial distributions unresolved. To address this challenge, we combined ion mobility spectrometry with mass spectrometry imaging for isomer-resolved ganglioside analysis. We assessed ganglioside complexity in wild-type (Npc2+/+) and NPC2-deficient mice with or without AAV-BR1-mediated NPC2 gene therapy (Npc2-/- AAV-BR1-NPC2 and Npc2-/- vehicle) using matrix-assisted laser desorption ionization (MALDI) MSI, and imaging-parallel reaction monitoring-parallel accumulation serial fragmentation (iPRM-PASEF-MS/MS) for in situ brain tissue analysis. Trapped ion mobility spectrometry (TIMS) enabled gas-phase separation of isomeric gangliosides, while iPRM-PASEF-MS/MS facilitated structural discrimination based on diagnostic fragment ions and identification of molecular modifications. Brain sections were analyzed by MALDI-MSI at 20m spatial resolution, with selected regions examined using post-ionization imaging by MALDI-2 at 5m. 59 mobility-resolved ganglioside features representing 23 putative annotations were identified, including separation and spatial mapping of GM1a/GM1b and GD1a/GD1b isomers. Notably, unreported modifications of gangliosides were identified, including GM1 fucosylation in Npc2-/- mice and GD1 O-acetylation exclusively detected in Npc2+/+ mice. Spatial ganglioside profiling by MSI demonstrated that gene therapy of Npc2-/- mice partially restored normal ganglioside localization in brain, indicating modulation of lipid storage. This study establishes isomer-resolved lipid imaging for investigating ganglioside alterations in disease models and the effects of therapeutic intervention.

biochemistry↗

bioRxiv2024

Endothelial and neuronal engagement by AAV-BR1 alleviates neurological symptoms and cholesterol deposition in a mouse model of Niemann-Pick type C2

BackgroundPatients with the genetic disorder Niemann-Pick type C2 disease (NP-C2) suffer from lysosomal accumulation of cholesterol causing both systemic and severe neurological symptoms. In a murine NP-C2 model, otherwise successful intravenous Niemann-Pick C2 protein (NPC2) replacement therapy fails to alleviate progressive neurodegeneration as infused NPC2 is unable to cross the blood-brain barrier (BBB). Genetic modification of brain endothelial cells (BECs) is thought to enable secretion of recombinant proteins thereby overcoming the restrictions of the BBB. We hypothesized that BBB-directed gene therapy using the AAV-BR1-NPC2 vector would transduce both BECs and neurons in a mouse model of NP-C2 (Npc2-/-). MethodsSix weeks old Npc2-/- mice were intravenously injected with the AAV-BR1-NPC2 vector. Post-mortem analyses included gene expression analyses, determination of NPC2 transduction in the CNS, and co-detection of cholesterol with NPC2 in neurons. ResultsThe vector exerted tropism for BECs and neurons resulting in a widespread NPC2 distribution in the brain with a concomitant reduction of cholesterol in adjacent neurons, presumably not transduced by the vector. ConclusionThe data suggests cross-correcting gene therapy to the brain via delivery of NPC2 from BECs and neurons.

neuroscience↗

bioRxiv2020

The blood-brain barrier studied in vitro across species

The blood-brain barrier (BBB) is formed by brain capillary endothelial cells (BECs) supported by pericytes and astrocytes. The BBB maintains homeostasis and protects the brain against toxic substances circulating in the blood, which consequently means that only a few drugs can pass the BBB. Thus for drug screening, understanding cell interactions, and pathology, in vitro BBB models have been developed using BECs from various animal sources. When comparing models of different species, differences exist especially in regards to the transendothelial electrical resistance (TEER). Thus, in the present study, we compared primary mice, rat, and porcine BECs (mBECs, rBECs, and pBECs) cultured in mono- and co-culture with astrocytes, to identify potential species-dependent differences that could explain the variations in TEER and aid to the selection of models for future in vitro BBB studies. The in vitro BBB models based on primary mBECs, rBECs, and pBECs were evaluated and compared in regards to major BBB characteristics. The barrier integrity was evaluated by the expression of tight junction proteins and measurements of TEER and apparent permeability (Papp). Furthermore, the cell size, the functionality of the P-glycoprotein (P-gp) efflux transporter, and the expression of the transferrin receptor were evaluated and compared. pBECs exhibit the highest TEER followed by rBECs and mBECs, but surprisingly the Papp was not that different, which might be explained by a significantly larger cell size of pBECs than rBECs and mBECs. The expression and organization of many tight junction proteins were in all three species influenced by co-culturing, which supports the findings that the TEER increases after co-culturing with astrocytes. Furthermore, all models had functional polarised P-gp efflux transporters and expressed the transferrin receptor. In conclusion, the choice of species for in vitro BBB modeling should be based on the purpose of the study.

neuroscience↗